These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6282559)

  • 21. [Tumor markers in bronchial cancer: do they have a role in daily practice?].
    Feintrenie X; Briancon S; Pichene M; Lamy P
    Rev Pneumol Clin; 1984; 40(6):345-54. PubMed ID: 6085181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Increased levels of alpha and beta subunits of chorionic gonadotropin in the serum of patients with primary lung cancer].
    Broniek A; Ochnio J; Rogińska E; Kwiek S; Rowińska-Zakrzewska E
    Pneumonol Pol; 1986 Aug; 54(8):348-52. PubMed ID: 3024136
    [No Abstract]   [Full Text] [Related]  

  • 23. Antidiuretic hormone in bronchogenic carcinoma.
    Morton JJ; Kelly P; Padfield PL
    Clin Endocrinol (Oxf); 1978 Oct; 9(4):357-70. PubMed ID: 214259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of serum levels of beta2-microglobulin and carcino-embryonic antigen in the follow-up of lung cancer (author's transl)].
    Ardiet C; Gonthier R; Pasquet P; Lahneche B
    Pathol Biol (Paris); 1978 Sep; 26(6):355-7. PubMed ID: 83584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Functional exploration of the antidiuretic hormone].
    Camps J; Pérez Ayuso RM; Martínez Vea A
    Med Clin (Barc); 1983 Jan; 80(2):85-8. PubMed ID: 6302409
    [No Abstract]   [Full Text] [Related]  

  • 27. [An evaluation of carcinoembryonic antigen (CEA), beta 2-microglobulin (BMG), and immunosuppressive acidic protein (IAP) in the serum of primary lung cancer patients].
    Higuchi Y
    Gan No Rinsho; 1986 Jan; 32(1):33-40. PubMed ID: 3005690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
    Milman N; Pedersen LM
    Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection.
    Yeh JJ; Liu FY; Hsu WH; Wang JJ; Ho ST; Kao A
    Lung; 2002; 180(5):273-9. PubMed ID: 12489021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased serum and urinary levels of a parathyroid hormone-related protein COOH terminus in non-small cell lung cancer patients.
    Nishigaki Y; Ohsaki Y; Toyoshima E; Kikuchi K
    Clin Cancer Res; 1999 Jun; 5(6):1473-81. PubMed ID: 10389935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The clinical significance serum N-POMC level in lung cancer patients].
    Li LY; Luo WC; Lu ZL
    Zhonghua Zhong Liu Za Zhi; 1994 Jul; 16(4):291-4. PubMed ID: 7805561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tumour-specific antibodies in the regional lymph nodes of patients with lung cancer (author's transl)].
    Matsubara Y; Funatsu T; Hatakenaka R; Kuwabara M; Taki T; Miyamoto Y; Kosaba S; Ninomiya K; Ikeda S
    Prax Klin Pneumol; 1980 Sep; 34(9):524-32. PubMed ID: 6256724
    [No Abstract]   [Full Text] [Related]  

  • 34. Significance of serum sialoglycoproteins in patients with lung cancer.
    Patel PS; Baxi BR; Balar DB
    Neoplasma; 1989; 36(1):53-9. PubMed ID: 2539569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neuron-specific enolase as a tumor marker in small cell bronchial carcinoma].
    Gasser RW; Herold M; Müller-Holzner E; Müller LC; Salzer GM; Huber H
    Dtsch Med Wochenschr; 1988 Nov; 113(44):1708-13. PubMed ID: 2846253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoglobulins and complement components in patients with lung cancer.
    Oner F; Savaş I; Numanoğlu N
    Tuberk Toraks; 2004; 52(1):19-23. PubMed ID: 15143368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elastin metabolism parameters in sera of patients with lung cancer.
    Gmiński J; Mykala-Cieśla J; Machalski M; Drózdz M
    Neoplasma; 1993; 40(1):41-4. PubMed ID: 8394514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Possible causes for an increased content of blood peptide hormones in small-cell lung cancer].
    Raĭkhlin NT; Smirnova EA; Blinova SA; Deĭneko GM; Bassalyk LS
    Vopr Onkol; 1989; 35(2):203-7. PubMed ID: 2564709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
    Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
    Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cytological classification of bronchial carcinoma (author's transl)].
    Droese M; Bayer E
    Dtsch Med Wochenschr; 1976 Sep; 101(39):1417-20. PubMed ID: 976111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.